Conclusions
Two BNT162b2/Pfizer doses are associated with a 48% reduction of SARS-CoV-2 incidence and a 91.3% reduction of death risk in residents from NHs facing a VOC-α outbreak. BNT162b2/Pfizer efficacy was partly predicted by post-vaccine RBD-IgG levels.
Key words: SARS-CoV-2; Covid-19; symptoms; nursing homes; residents; BNT162b2/Pfizer vaccine; efficacy; antibody response; nucleocapsid antigenemia; neutralizing antibodies